This question tests cardiovascular risk and prevention for USMLE Step 2 CK, specifically understanding smoking cessation in young adults. Cardiovascular risk management involves addressing smoking as a top priority. In the vignette, the patient's smoking, obesity, hypertension, and lipids highlight cessation needs. The correct answer, 'Recommend complete smoking cessation with counseling,' aligns with guidelines over alternatives like vaping. Choice A, switching to vaping, is not safer long-term. To help students: Discuss cessation resources, assess dependence, and debunk reduced-harm myths.

This question tests cardiovascular risk and prevention for USMLE Step 2 CK, specifically understanding risk assessment and preventive strategies in diabetic patients. Cardiovascular risk management involves assessing risk factors like diabetes, hypertension, dyslipidemia, and sedentary lifestyle, with preventive strategies prioritizing statin therapy for high-risk individuals. In the vignette, the patient's type 2 diabetes, elevated LDL, family history of premature CAD, and other risks warrant aggressive lipid management. The correct answer, 'Start moderate- to high-intensity statin therapy,' aligns with guidelines recommending statins for adults aged 40-75 with diabetes to reduce ASCVD events. Choice C, starting daily aspirin regardless of bleeding risk, is inappropriate as aspirin for primary prevention in diabetes is individualized and not automatic. To help students: Focus on ACC/AHA cholesterol guidelines for diabetics, differentiate primary vs. secondary prevention, and avoid overusing aspirin without risk-benefit assessment. Practice identifying statin intensity levels and indications.

This question tests cardiovascular risk and prevention for USMLE Step 2 CK, specifically understanding lipid management in diabetic patients with additional risk factors. Cardiovascular risk management involves evaluating ASCVD risk in diabetics, where guidelines recommend statin therapy for those aged 40-75 to reduce events, alongside lifestyle modifications. In the vignette, the patient's type 2 diabetes, postmenopausal status, family history of early MI, sedentary lifestyle, and elevated LDL indicate a high risk, warranting pharmacologic intervention despite controlled A1c and blood pressure. The correct answer, 'Start moderate- to high-intensity statin therapy,' is most indicated as it directly targets LDL reduction and is first-line for cardiovascular risk reduction in this profile per ACC/AHA guidelines. Choice B, starting fenofibrate, is incorrect because it is not primary for LDL management and is typically used for severe hypertriglyceridemia. To help students: Focus on memorizing statin indications in diabetes, including risk enhancers like family history, and avoid common pitfalls such as prioritizing therapies like niacin that have limited evidence. Practice integrating patient profiles with guidelines to select evidence-based adjustments over unnecessary changes like stopping effective medications.

This question tests cardiovascular risk and prevention for USMLE Step 2 CK, specifically understanding risk reduction in young adults. Cardiovascular risk management involves assessing smoking, obesity, and hypertension, with preventive strategies prioritizing cessation. In the vignette, the patient's smoking, obesity, stress, and BP elevate long-term risk. The correct answer, 'Recommend smoking cessation with pharmacotherapy options,' aligns with guidelines for comprehensive support to quit. Choice A, starting aspirin, is not indicated for primary prevention here. To help students: Discuss cessation pharmacotherapy, assess readiness to quit, and calculate lifetime vs. 10-year risk.

This question tests cardiovascular risk and prevention for USMLE Step 2 CK, specifically understanding modifiable risk factors in young adults. Cardiovascular risk management involves assessing factors like smoking, obesity, hypertension, and dyslipidemia, with preventive strategies emphasizing smoking cessation as a high-impact intervention. In the vignette, the patient's smoking history, obesity, elevated BP, and dyslipidemia significantly elevate long-term ASCVD risk. The correct answer, 'Recommend complete smoking cessation with support,' aligns with guidelines prioritizing smoking cessation to dramatically reduce CV events. Choice E, starting aspirin immediately, is not indicated for primary prevention in this low short-term risk young adult due to bleeding risks. To help students: Highlight the multiplicative effect of smoking on other risks, review cessation aids like varenicline or counseling, and understand when advanced imaging like CT angiography is unnecessary.

Guidelines recommend that all patients with diabetes mellitus aged 40 to 75 years should be treated with at least a moderate-intensity statin, regardless of their baseline LDL cholesterol or calculated 10-year ASCVD risk. High-intensity statin therapy is recommended for diabetic patients with a higher ASCVD risk (≥20%) or multiple ASCVD risk factors. Since this patient's risk is 8%, a moderate-intensity statin (e.g., atorvastatin 10-20 mg, rosuvastatin 5-10 mg) is the most appropriate initial choice.

The most appropriate next step for this patient is to calculate his 10-year risk of atherosclerotic cardiovascular disease (ASCVD) using the Pooled Cohort Equations. This calculation incorporates age, sex, race, cholesterol levels, blood pressure, smoking status, and diabetes status to estimate the 10-year risk of a major cardiovascular event. The result of this risk assessment is crucial for guiding decisions about primary prevention, including the initiation and intensity of statin therapy. For adults aged 40-75, this is the first step before deciding on treatment.

This patient has multiple risk factors including type 2 diabetes and hypertension, and her calculated 10-year ASCVD risk is >20%, placing her in the high-risk category for a primary prevention. According to current guidelines, patients at high risk should be started on high-intensity statin therapy. High-intensity statins include atorvastatin 40-80 mg or rosuvastatin 20-40 mg. Therefore, initiating atorvastatin 40 mg is the most appropriate choice. Rosuvastatin 10 mg is a moderate-intensity statin.

While all listed options are beneficial for blood pressure control, weight loss has the most significant effect. On average, blood pressure is reduced by approximately 1 mmHg for every 1 kg of weight loss. A 10 kg weight loss can lead to a 5-10 mmHg reduction in systolic blood pressure. The DASH diet can lower SBP by about 11 mmHg, but achieving this requires significant dietary changes. Sodium restriction and exercise have slightly smaller, though still important, effects. Given her obesity, weight loss is the most impactful single intervention.

This patient is experiencing statin-associated muscle symptoms (SAMS). Given her history of peripheral artery disease, she is at very high risk for cardiovascular events and derives a significant benefit from statin therapy. The recommended approach for SAMS is to stop the initial statin, wait for symptoms to resolve, and then re-challenge with a different statin, often at a lower dose or with a different dosing schedule. Rosuvastatin is a hydrophilic statin and may be better tolerated. Starting at a low dose (5 mg) is a safe and appropriate strategy.